Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.

ABSTRACT:

Purpose

Few efforts have been made to integrate a next generation sequencing (NGS) panel into standard clinical treatment of ovarian cancer. The aim of this study was to investigate the clinical utility of NGS and to identify clinically impactful information beyond targetable alterations.

Materials and methods

We conducted a retrospective review of 84 patients with ovarian cancer who underwent NGS between March 1, 2017, and July 31, 2018, at the Yonsei Cancer Hospital. We extracted DNA from formalin-fixed, paraffin-embedded tissue samples of ovarian cancer. The TruSight Tumor 170 gene panel was used to prepare libraries, and the MiSeq instrument was used for NGS.

Results

Of the 84 patients, 55 (65.1%) had high-grade serous carcinomas. Seventy-three (86.7%) patients un

SUBMITTER: Lee YJ 

PROVIDER: S-EPMC6753345 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature